HEALTH NEWS
Covaxin 77.8% effective in phase 3 trial data: Sources
According to data from Phase III trials conducted on 25,800 participants across India, the Covaxin is 77.8 per cent effective in protecting against COVID-19.
According to sources, the trial data and results were studied and recommended for approval by the DCGI’s Subject Expert Committee on Tuesday.
The data was submitted to the DCGI over the weekend.
However, the data has not yet been published in an internationally recognised, peer-reviewed journal. Earlier this month Bharat Biotech said publication would only happen after submission to the regulator.
It is already known that the data available and analysed at that stage also showed a 100 per cent reduction in chances of hospitalisation in case of infection.
And, the Phase III data approval will likely also help Bharat Biotech secure an EUL (emergency use listing) from the World Health Organization.